The soluble epoxide hydrolase inhibitor GSK2256294 decreases the proportion of adipose pro-inflammatory T cells
Mashayekhi M, Wanjalla CN, Warren CM, Simmons JD, Ghoshal K, Pilkinton M, Bailin SS, Gabriel CL, Pozzi A, Koethe JR, Brown NJ, Kalams SA, Luther JM. The soluble epoxide hydrolase inhibitor GSK2256294 decreases the proportion of adipose pro-inflammatory T cells. Prostaglandins And Other Lipid Mediators 2021, 158: 106604. PMID: 34922004, PMCID: PMC8742790, DOI: 10.1016/j.prostaglandins.2021.106604.Peer-Reviewed Original ResearchConceptsPro-inflammatory T cellsEpoxyeicosatrienoic acidsSoluble epoxide hydrolaseSystemic inflammationT cellsAdipose tissueSubcutaneous abdominal adipose tissueEnzyme soluble epoxide hydrolaseComplex immune environmentT cell profileAbdominal adipose tissuePrediabetic adultsImmune environmentObese individualsSEH inhibitionObese personsTumor necrosisObese animalsInflammationCrossover designCell profilesGSK2256294Epoxide hydrolaseCentral contributorTissueGSK2256294 Decreases sEH (Soluble Epoxide Hydrolase) Activity in Plasma, Muscle, and Adipose and Reduces F2-Isoprostanes but Does Not Alter Insulin Sensitivity in Humans
Luther JM, Ray J, Wei D, Koethe JR, Hannah L, DeMatteo A, Manning R, Terker AS, Peng D, Nian H, Yu C, Mashayekhi M, Gamboa J, Brown NJ. GSK2256294 Decreases sEH (Soluble Epoxide Hydrolase) Activity in Plasma, Muscle, and Adipose and Reduces F2-Isoprostanes but Does Not Alter Insulin Sensitivity in Humans. Hypertension 2021, 78: 1092-1102. PMID: 34455816, PMCID: PMC8429121, DOI: 10.1161/hypertensionaha.121.17659.Peer-Reviewed Original Research